Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Quantitative Proteomic Analysis of Simian Primary Hepatocytes Reveals Candidate Molecular Markers for Permissiveness to Relapsing Malaria Plasmodium cynomolgi.

Dembele L, Gupta DK, Dutta B, Chua ACY, Sze SK, Bifani P.

Proteomics. 2019 Oct;19(19):e1900021. doi: 10.1002/pmic.201900021.

PMID:
31444903
2.

Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages.

Chua ACY, Ong JJY, Malleret B, Suwanarusk R, Kosaisavee V, Zeeman AM, Cooper CA, Tan KSW, Zhang R, Tan BH, Abas SN, Yip A, Elliot A, Joyner CJ, Cho JS, Breyer K, Baran S, Lange A, Maher SP, Nosten F, Bodenreider C, Yeung BKS, Mazier D, Galinski MR, Dereuddre-Bosquet N, Le Grand R, Kocken CHM, Rénia L, Kyle DE, Diagana TT, Snounou G, Russell B, Bifani P.

Nat Commun. 2019 Aug 12;10(1):3635. doi: 10.1038/s41467-019-11332-4.

3.

Hepatic spheroids used as an in vitro model to study malaria relapse.

Chua ACY, Ananthanarayanan A, Ong JJY, Wong JY, Yip A, Singh NH, Qu Y, Dembele L, McMillian M, Ubalee R, Davidson S, Tungtaeng A, Imerbsin R, Gupta K, Andolina C, Lee F, S-W Tan K, Nosten F, Russell B, Lange A, Diagana TT, Rénia L, Yeung BKS, Yu H, Bifani P.

Biomaterials. 2019 Sep;216:119221. doi: 10.1016/j.biomaterials.2019.05.032. Epub 2019 May 22.

4.

The Plasmodium liver-specific protein 2 (LISP2) is an early marker of liver stage development.

Gupta DK, Dembele L, Voorberg-van der Wel A, Roma G, Yip A, Chuenchob V, Kangwanrangsan N, Ishino T, Vaughan AM, Kappe SH, Flannery EL, Sattabongkot J, Mikolajczak S, Bifani P, Kocken CH, Diagana TT.

Elife. 2019 May 16;8. pii: e43362. doi: 10.7554/eLife.43362.

5.

The addition of avibactam renders piperacillin an effective treatment for Mycobacterium abscessus infection in an in vivo model.

Meir M, Bifani P, Barkan D.

Antimicrob Resist Infect Control. 2018 Dec 13;7:151. doi: 10.1186/s13756-018-0448-4. eCollection 2018.

6.

Imidazolopiperazines Kill both Rings and Dormant Rings in Wild-Type and K13 Artemisinin-Resistant Plasmodium falciparum In Vitro.

Dembele L, Gupta DK, Lim MY, Ang X, Selva JJ, Chotivanich K, Nguon C, Dondorp AM, Bonamy GMC, Diagana TT, Bifani P.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02235-17. doi: 10.1128/AAC.02235-17. Print 2018 May.

7.

A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite Plasmodium cynomolgi.

Voorberg-van der Wel A, Roma G, Gupta DK, Schuierer S, Nigsch F, Carbone W, Zeeman AM, Lee BH, Hofman SO, Faber BW, Knehr J, Pasini E, Kinzel B, Bifani P, Bonamy GMC, Bouwmeester T, Kocken CHM, Diagana TT.

Elife. 2017 Dec 7;6. pii: e29605. doi: 10.7554/eLife.29605.

8.

Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi.

Kosaisavee V, Suwanarusk R, Chua ACY, Kyle DE, Malleret B, Zhang R, Imwong M, Imerbsin R, Ubalee R, Sámano-Sánchez H, Yeung BKS, Ong JJY, Lombardini E, Nosten F, Tan KSW, Bifani P, Snounou G, Rénia L, Russell B.

Blood. 2017 Sep 14;130(11):1357-1363. doi: 10.1182/blood-2017-02-764787. Epub 2017 Jul 11.

9.

The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites.

Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MY, Bodenreider C, Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagana TT, Bifani P.

Sci Rep. 2017 May 24;7(1):2325. doi: 10.1038/s41598-017-02440-6.

10.

Genomic epidemiology of Lineage 4 Mycobacterium tuberculosis subpopulations in New York City and New Jersey, 1999-2009.

Brown TS, Narechania A, Walker JR, Planet PJ, Bifani PJ, Kolokotronis SO, Kreiswirth BN, Mathema B.

BMC Genomics. 2016 Nov 21;17(1):947.

11.

UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes.

Lim MY, LaMonte G, Lee MCS, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A, Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GMC, Ho PC, Yeung BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P.

Nat Microbiol. 2016 Sep 19;1:16166. doi: 10.1038/nmicrobiol.2016.166.

12.

Mutations in the Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL) Confer Multidrug Resistance.

LaMonte G, Lim MY, Wree M, Reimer C, Nachon M, Corey V, Gedeck P, Plouffe D, Du A, Figueroa N, Yeung B, Bifani P, Winzeler EA.

MBio. 2016 Jul 5;7(4). pii: e00696-16. doi: 10.1128/mBio.00696-16.

13.

Structure and mapping of spontaneous mutational sites of PyrR from Mycobacterium tuberculosis.

Ghode P, Ramachandran S, Bifani P, Sivaraman J.

Biochem Biophys Res Commun. 2016 Mar 18;471(4):409-15. doi: 10.1016/j.bbrc.2016.02.071. Epub 2016 Feb 18.

PMID:
26902118
14.

Structural basis of mapping the spontaneous mutations with 5-flurouracil in uracil phosphoribosyltransferase from Mycobacterium tuberculosis.

Ghode P, Jobichen C, Ramachandran S, Bifani P, Sivaraman J.

Biochem Biophys Res Commun. 2015 Nov 20;467(3):577-82. doi: 10.1016/j.bbrc.2015.09.133. Epub 2015 Oct 8.

PMID:
26456658
15.

Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis.

Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, Bifani P.

Antimicrob Agents Chemother. 2015 Sep;59(9):5316-23. doi: 10.1128/AAC.00308-15. Epub 2015 Jun 22.

16.

Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria.

Soetaert K, Rens C, Wang XM, De Bruyn J, Lanéelle MA, Laval F, Lemassu A, Daffé M, Bifani P, Fontaine V, Lefèvre P.

Antimicrob Agents Chemother. 2015 Aug;59(8):5057-60. doi: 10.1128/AAC.04856-14. Epub 2015 Jun 1.

17.

Genomic analysis and growth characteristic of dengue viruses from Makassar, Indonesia.

Sasmono RT, Wahid I, Trimarsanto H, Yohan B, Wahyuni S, Hertanto M, Yusuf I, Mubin H, Ganda IJ, Latief R, Bifani PJ, Shi PY, Schreiber MJ.

Infect Genet Evol. 2015 Jun;32:165-77. doi: 10.1016/j.meegid.2015.03.006. Epub 2015 Mar 14.

18.

Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents.

Yokokawa F, Wang G, Chan WL, Ang SH, Wong J, Ma I, Rao SP, Manjunatha U, Lakshminarayana SB, Herve M, Kounde C, Tan BH, Thayalan P, Ng SH, Nanjundappa M, Ravindran S, Gee P, Tan M, Wei L, Goh A, Chen PY, Lee KS, Zhong C, Wagner T, Dix I, Chatterjee AK, Pethe K, Kuhen K, Glynne R, Smith P, Bifani P, Jiricek J.

ACS Med Chem Lett. 2013 Apr 1;4(5):451-5. doi: 10.1021/ml400071a. eCollection 2013 May 9. Erratum in: ACS Med Chem Lett. 2014 Apr 10;5(4):451.

19.

Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.

Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, Ng SH, Nanjundappa M, Ravindran S, Seah PG, Thayalan P, Lim SH, Lee BH, Goh A, Barnes WS, Chen Z, Gagaring K, Chatterjee AK, Pethe K, Kuhen K, Walker J, Feng G, Babu S, Zhang L, Blasco F, Beer D, Weaver M, Dartois V, Glynne R, Dick T, Smith PW, Diagana TT, Manjunatha UH.

Sci Transl Med. 2013 Dec 4;5(214):214ra168. doi: 10.1126/scitranslmed.3007355.

20.

Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.

Kondreddi RR, Jiricek J, Rao SP, Lakshminarayana SB, Camacho LR, Rao R, Herve M, Bifani P, Ma NL, Kuhen K, Goh A, Chatterjee AK, Dick T, Diagana TT, Manjunatha UH, Smith PW.

J Med Chem. 2013 Nov 14;56(21):8849-59. doi: 10.1021/jm4012774. Epub 2013 Oct 22.

PMID:
24090347
21.

Exploring the mode of action of bioactive compounds by microfluidic transcriptional profiling in mycobacteria.

Murima P, de Sessions PF, Lim V, Naim AN, Bifani P, Boshoff HI, Sambandamurthy VK, Dick T, Hibberd ML, Schreiber M, Rao SP.

PLoS One. 2013 Jul 31;8(7):e69191. doi: 10.1371/journal.pone.0069191. Print 2013.

22.

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SP, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J.

Nat Med. 2013 Sep;19(9):1157-60. doi: 10.1038/nm.3262. Epub 2013 Aug 4.

PMID:
23913123
23.

para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.

Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR.

J Biol Chem. 2013 Aug 9;288(32):23447-56. doi: 10.1074/jbc.M113.475798. Epub 2013 Jun 18. Erratum in: J Biol Chem. 2013 Oct 4;288(40):28951.

24.

Heterogeneity of Mycobacterium tuberculosis strains in Makassar, Indonesia.

Sasmono RT, Massi MN, Setianingsih TY, Wahyuni S; Anita, Halik H, Yusuf I, Dick T, Sola C, Bifani PJ, Phyu S.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1441-8. doi: 10.5588/ijtld.12.0055.

PMID:
23044445
25.

Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis.

Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P.

Antimicrob Agents Chemother. 2012 Oct;56(10):5186-93. doi: 10.1128/AAC.05385-11. Epub 2012 Jul 23.

26.

CC8 MRSA strains harboring SCCmec type IVc are predominant in Colombian hospitals.

Jiménez JN, Ocampo AM, Vanegas JM, Rodriguez EA, Mediavilla JR, Chen L, Muskus CE, Vélez LA, Rojas C, Restrepo AV, Ospina S, Garcés C, Franco L, Bifani P, Kreiswirth BN, Correa MM.

PLoS One. 2012;7(6):e38576. doi: 10.1371/journal.pone.0038576. Epub 2012 Jun 20.

27.

A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis.

Mak PA, Rao SP, Ping Tan M, Lin X, Chyba J, Tay J, Ng SH, Tan BH, Cherian J, Duraiswamy J, Bifani P, Lim V, Lee BH, Ling Ma N, Beer D, Thayalan P, Kuhen K, Chatterjee A, Supek F, Glynne R, Zheng J, Boshoff HI, Barry CE 3rd, Dick T, Pethe K, Camacho LR.

ACS Chem Biol. 2012 Jul 20;7(7):1190-7. doi: 10.1021/cb2004884. Epub 2012 Apr 25.

28.

Epidemiologic consequences of microvariation in Mycobacterium tuberculosis.

Mathema B, Kurepina N, Yang G, Shashkina E, Manca C, Mehaffy C, Bielefeldt-Ohmann H, Ahuja S, Fallows DA, Izzo A, Bifani P, Dobos K, Kaplan G, Kreiswirth BN.

J Infect Dis. 2012 Mar 15;205(6):964-74. doi: 10.1093/infdis/jir876. Epub 2012 Feb 7.

29.

BCG induces protection against Mycobacterium tuberculosis infection in the Wistar rat model.

Singhal A, Mathys V, Kiass M, Creusy C, Delaire B, Aliouat el M, Dartois V, Kaplan G, Bifani P.

PLoS One. 2011;6(12):e28082. doi: 10.1371/journal.pone.0028082. Epub 2011 Dec 5.

30.

Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat.

Heng Y, Seah PG, Siew JY, Tay HC, Singhal A, Mathys V, Kiass M, Bifani P, Dartois V, Hervé M.

Tuberculosis (Edinb). 2011 Jul;91(4):339-41. doi: 10.1016/j.tube.2011.05.003. Epub 2011 Jun 1.

PMID:
21636324
31.

T cell monitoring of chemotherapy in experimental rat tuberculosis.

Foo DG, Tay HC, Siew JY, Singhal A, Camacho L, Bifani P, Dartois V, Hervé M.

Antimicrob Agents Chemother. 2011 Aug;55(8):3677-83. doi: 10.1128/AAC.00136-11. Epub 2011 May 31.

32.

Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection.

Singhal A, Aliouat el M, Hervé M, Mathys V, Kiass M, Creusy C, Delaire B, Tsenova L, Fleurisse L, Bertout J, Camacho L, Foo D, Tay HC, Siew JY, Boukhouchi W, Romano M, Mathema B, Dartois V, Kaplan G, Bifani P.

PLoS One. 2011 Apr 12;6(4):e18632. doi: 10.1371/journal.pone.0018632.

33.

Extremely high prevalence of multidrug resistant tuberculosis in Murmansk, Russia: a population-based study.

Mäkinen J, Marjamäki M, Haanperä-Heikkinen M, Marttila H, Endourova LB, Presnova SE, Mathys V, Bifani P, Ruohonen R, Viljanen MK, Soini H.

Eur J Clin Microbiol Infect Dis. 2011 Sep;30(9):1119-26. doi: 10.1007/s10096-011-1200-7. Epub 2011 Mar 11.

PMID:
21394425
34.

Phylogeny of Mycobacterium tuberculosis Beijing strains constructed from polymorphisms in genes involved in DNA replication, recombination and repair.

Mestre O, Luo T, Dos Vultos T, Kremer K, Murray A, Namouchi A, Jackson C, Rauzier J, Bifani P, Warren R, Rasolofo V, Mei J, Gao Q, Gicquel B.

PLoS One. 2011 Jan 20;6(1):e16020. doi: 10.1371/journal.pone.0016020.

35.

Biochemical and immunological characterization of a cpn60.1 knockout mutant of Mycobacterium bovis BCG.

Wang XM, Lu C, Soetaert K, S'Heeren C, Peirs P, Lanéelle MA, Lefèvre P, Bifani P, Content J, Daffé M, Huygen K, De Bruyn J, Wattiez R.

Microbiology. 2011 Apr;157(Pt 4):1205-19. doi: 10.1099/mic.0.045120-0. Epub 2010 Dec 2.

PMID:
21127129
36.

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T.

Nat Commun. 2010 Aug 24;1:57. doi: 10.1038/ncomms1060.

37.

Genotyping of Mycobacterium tuberculosis clinical isolates using IS6110-based restriction fragment length polymorphism analysis.

Bifani P, Kurepina N, Mathema B, Wang XM, Kreiswirth B.

Methods Mol Biol. 2009;551:173-88. doi: 10.1007/978-1-60327-999-4_14.

PMID:
19521875
38.

A novel and more sensitive loop-mediated isothermal amplification assay targeting IS6110 for detection of Mycobacterium tuberculosis complex.

Aryan E, Makvandi M, Farajzadeh A, Huygen K, Bifani P, Mousavi SL, Fateh A, Jelodar A, Gouya MM, Romano M.

Microbiol Res. 2010 Mar 31;165(3):211-20. doi: 10.1016/j.micres.2009.05.001. Epub 2009 Jun 10.

39.

Variable-number tandem repeat 3690 polymorphism in Indian clinical isolates of Mycobacterium tuberculosis and its influence on transcription.

Akhtar P, Singh S, Bifani P, Kaur S, Srivastava BS, Srivastava R.

J Med Microbiol. 2009 Jun;58(Pt 6):798-805. doi: 10.1099/jmm.0.002550-0.

PMID:
19429757
40.

Synthetic EthR inhibitors boost antituberculous activity of ethionamide.

Willand N, Dirié B, Carette X, Bifani P, Singhal A, Desroses M, Leroux F, Willery E, Mathys V, Déprez-Poulain R, Delcroix G, Frénois F, Aumercier M, Locht C, Villeret V, Déprez B, Baulard AR.

Nat Med. 2009 May;15(5):537-44. doi: 10.1038/nm.1950. Epub 2009 May 3.

PMID:
19412174
41.

Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.

Mathys V, Wintjens R, Lefevre P, Bertout J, Singhal A, Kiass M, Kurepina N, Wang XM, Mathema B, Baulard A, Kreiswirth BN, Bifani P.

Antimicrob Agents Chemother. 2009 May;53(5):2100-9. doi: 10.1128/AAC.01197-08. Epub 2009 Feb 23.

42.

Molecular analysis of high-level ciprofloxacin resistance in Salmonella enterica serovar Typhi and S. Paratyphi A: need to expand the QRDR region?

Capoor MR, Nair D, Walia NS, Routela RS, Grover SS, Deb M, Aggarwal P, Pillai PK, Bifani PJ.

Epidemiol Infect. 2009 Jun;137(6):871-8. doi: 10.1017/S0950268808001076. Epub 2008 Aug 8.

PMID:
18687156
43.

The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population.

Bifani P, Mathema B, Kurepina N, Shashkina E, Bertout J, Blanchis AS, Moghazeh S, Driscoll J, Gicquel B, Frothingham R, Kreiswirth BN.

J Infect Dis. 2008 Jul 1;198(1):90-4. doi: 10.1086/588822.

PMID:
18498237
44.

IS1096-mediated DNA rearrangements play a key role in genome evolution of Mycobacterium smegmatis.

Wang XM, Galamba A, Warner DF, Soetaert K, Merkel JS, Kalai M, Bifani P, Lefèvre P, Mizrahi V, Content J.

Tuberculosis (Edinb). 2008 Sep;88(5):399-409. doi: 10.1016/j.tube.2008.02.003. Epub 2008 Apr 24.

PMID:
18439874
45.

Detecting the molecular scars of evolution in the Mycobacterium tuberculosis complex by analyzing interrupted coding sequences.

Deshayes C, Perrodou E, Euphrasie D, Frapy E, Poch O, Bifani P, Lecompte O, Reyrat JM.

BMC Evol Biol. 2008 Mar 6;8:78. doi: 10.1186/1471-2148-8-78.

46.

Standardised PCR-based molecular epidemiology of tuberculosis.

Allix-Béguec C, Supply P, Wanlin M, Bifani P, Fauville-Dufaux M.

Eur Respir J. 2008 May;31(5):1077-84. Epub 2007 Dec 19.

47.

Functional role of the PE domain and immunogenicity of the Mycobacterium tuberculosis triacylglycerol hydrolase LipY.

Mishra KC, de Chastellier C, Narayana Y, Bifani P, Brown AK, Besra GS, Katoch VM, Joshi B, Balaji KN, Kremer L.

Infect Immun. 2008 Jan;76(1):127-40. Epub 2007 Oct 15.

48.

Salmonella enterica serovar typhi: molecular analysis of strains with decreased susceptibility and resistant to ciprofloxacin in India from 2001-2003.

Capoor MR, Nair D, Aggarwal P, Mathys V, Dehem M, Bifani PJ.

Braz J Infect Dis. 2007 Aug;11(4):423-5.

PMID:
17873998
49.

Molecular and epidemiological evidence for spread of multiresistant methicillin-susceptible Staphylococcus aureus strains in hospitals.

Donnio PY, Février F, Bifani P, Dehem M, Kervégant C, Wilhelm N, Gautier-Lerestif AL, Lafforgue N, Cormier M; MR-MSSA Study Group of the Collège de Bactériologie-Virologie-Hygiène des Hôpitaux de France, Le Coustumier A.

Antimicrob Agents Chemother. 2007 Dec;51(12):4342-50. Epub 2007 Aug 20.

50.

Molecular epidemiology of tuberculosis: current insights.

Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN.

Clin Microbiol Rev. 2006 Oct;19(4):658-85. Review.

Supplemental Content

Loading ...
Support Center